BRADSHER NEAL C 4
4 · Lineage Cell Therapeutics, Inc. · Filed Jul 3, 2023
Insider Transaction Report
Form 4
Bradsher Neal C
10% Owner
Transactions
- Award
OPTION TO PURCHASE COMMON SHARES
2023-07-01+50,000→ 50,000 totalExercise: $1.41Exp: 2033-07-01→ COMMON SHARES (50,000 underlying)
Holdings
- 40,000
OPTION TO PURCHASE COMMON SHARES
Exercise: $0.83Exp: 2030-07-01→ COMMON SHARES (40,000 underlying) - 50,000
OPTION TO PURCHASE COMMON SHARES
Exercise: $1.57Exp: 2032-07-01→ COMMON SHARES (50,000 underlying) - 40,000
OPTION TO PURCHASE COMMON SHARES
Exercise: $1.03Exp: 2029-06-30→ COMMON SHARES (40,000 underlying) - 50,000
OPTION TO PURCHASE COMMON SHARES
Exercise: $2.86Exp: 2031-07-01→ COMMON SHARES (50,000 underlying)
Footnotes (3)
- [F1]These options will vest and become exercisable on July 1, 2024, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date.
- [F2]These options were granted to the Reporting Person by the Issuer on July 1, 2023 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
- [F3]These options are currently exercisable.